Neuroprotection seeks to restrict injury to the brain parenchyma following an ischaemic
insult by preventing salvageable neurons from dying. The concept of neuroprotection has …

Highlights•Clinical trials with neuroprotective drugs have failed in stroke.•Glutamate and
GABA crucially contribute to ischemic pathobiology.•Grabbing glutamate or targeting …

Organophosphate (OP) poisoning can trigger cholinergic crisis, a life-threatening toxidrome
that includes seizures and status epilepticus. These acute toxic responses are associated …

Systemic injection of thrombolytic drugs is the gold standard treatment for non-invasive
blood clot resolution. The most serious risks associated with the intravenous injection of …

Many neurons undergo apoptosis after ischemic stroke. In the brain, neurogenesis has the
potential for neuronal replacement and can be activated by external conditions to repair the …

Background and Purpose—The low-dose (0.6 mg/kg) alteplase strategy to treat acute
ischemic stroke patients became widespread in East Asian countries, without rigorous …

The amino acid L-arginine serves as substrate for the nitric oxide synthase which is crucial
in vascular function and disease. Derivatives of arginine, such as asymmetric (ADMA) and …

Stroke is an enormous public health problem with an imperative need for more effective
therapy. Recombinant tissue plasminogen activator is the only licensed drug for acute …

For decades, numerous pharmacological and non-pharmacological strategies have been
evaluated without success to limit the consequences of the ischemic cascade, but more …

Background and Purpose Recombinant tissue plasminogen activator (rtPA) is the only
effective drug approved by US FDA to treat ischemic stroke, and it contains pleiotropic …